Regemat 3D
Armilla
About Regemat 3D
REGEMAT 3D is a biotech company focused on regenerative medicine and pioneer in a new and promising area called bioprinting, that uses 3D printing technologies for regenerative therapies. REGEMAT3D is a bioprinting modular system that integrates the latest advances in 3D printing and regenerative therapies to offer adapted solutions to fulfil research's needs. A tested and validated systems, it is adaptable to different types of tissues, to research the biggest unsolved biotechnology problems and to battle different kinds of pathologies, such as; Cardiovascular Disease (CVD), Peripheral Vascular Disease (PVD), Non-healing wounds, Spinal cord injury, Alzheimer´s Disease (AD), Parkinson´s Disease (PD), Musculoskeletal Disorders (MSDs), Autoimmune Disorders, Stroke, Diabetes, and Ocular Disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $1.1M
- Last round: Equity Crowdfunding (Mar 2022)
- Website: regemat3d.com
- Phone: +34 958 637 124
Industries & Categories
3D Printing, Biotechnology, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/regemat-3d-65673 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.